Fresenius Medical Care AG (ETR:FME - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of €40.39 ($42.26) and traded as high as €45.35 ($47.45). Fresenius Medical Care shares last traded at €44.68 ($46.75), with a volume of 247,059 shares trading hands.

The firm has a market capitalization of $13.08 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 0.42 and a beta of 0.86. The business's 50-day simple moving average is €45.16 and its two-hundred day simple moving average is €40.52. The company has a quick ratio of 0.80, a current ratio of 1.37 and a debt-to-equity ratio of 82.24.

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Before you consider Fresenius Medical Care, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.

While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.